SIGN IN YOUR ACCOUNT TO HAVE ACCESS TO DIFFERENT FEATURES

FORGOT YOUR PASSWORD?

FORGOT YOUR DETAILS?

AAH, WAIT, I REMEMBER NOW!
+1 786 238 2170

Global Stem Cells GroupGlobal Stem Cells Group

  • Home
  • Our Story
  • Speakers
  • Investors
  • Companies
  • Press Releases
  • Blog
CONTACT
  • Home
  • Press Releases
  • Archive from category "Press Releases"
  • Page 2
November 19, 2026

Category: Press Releases

ISSCA Announces Global Summit in Cancun, Mexico, September 25–27

Thursday, August 13, 2026 by Sarah Barroso

FOR IMMEDIATE RELEASE

  • Summit features specialized workshops and certification tracks alongside international faculty at the JW Marriott Cancun Resort & Spa
  • Event is expected to draw more than 500 physicians, researchers, and regenerative medicine leaders to ISSCA’s flagship Cancun venue
  • Global Summit contributes to ISSCA’s international education ecosystem and Global Stem Cells Group’s worldwide presence

MIAMI, FL — The International Society for Stem Cell Application (ISSCA), the physician-education division of Global Stem Cells Group and Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG), today announced its 2026 Global Summit — ISSCA 125 — taking place September 25–27 at the JW Marriott Cancun Resort & Spa.

The Summit is expected to draw more than 500 physicians and professionals, with hundreds already registered, across specialized workshops and certification tracks including the organization’s flagship and peptide-medicine certifications, alongside international faculty, published authors, researchers, and physicians and leaders across regenerative medicine, longevity, and biotechnology.

ISSCA, founded in 2009, has trained more than 12,000 physicians across more than 45 countries to date. The Global Summit is positioned as a flagship contribution to ISSCA’s international education ecosystem and Global Stem Cells Group’s broader global footprint.

“Cancun has become something of a home base for ISSCA’s most ambitious programming,” said David Christensen, Chief Executive Officer and President of Regenerative Medical Technology Group, Inc. “The Global Summit is where physicians from the widest range of countries come together in one place, and that’s exactly the kind of international network effect we’re trying to build.”

About Regenerative Medical Technology Group, Inc.

Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG) is an SEC-reporting regenerative medicine company operating through its wholly owned subsidiary Global Stem Cells Group and Global Stem Cells Group’s operating divisions — Cellgenic, the International Society for Stem Cell Application (ISSCA), and Cellular Hope Institute. The Company’s network reaches physicians and patients across more than 30 countries, combining biologics and regenerative-medicine product commercialization, physician education and certification, and physician-directed clinical services. RMTG’s stated mission is to help physicians make the benefits of regenerative medicine available to patients worldwide.

About ISSCA

The International Society for Stem Cell Application (ISSCA), the physician-education division of Global Stem Cells Group and Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG), was founded in 2009 and has trained more than 12,000 physicians across more than 45 countries in regenerative medicine, longevity medicine, and related disciplines through certifications, fellowships, conferences, and online education.

Forward-Looking Statements

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, and other factors — including regulatory developments, market acceptance, operational execution, competitive conditions, currency and economic factors, and the Company’s ability to maintain compliance with applicable laws — that could cause actual results to differ materially from those expressed or implied. Words such as “plan,” “forecast,” “anticipate,” “estimate,” “project,” “intend,” “expect,” “should,” “believe,” and similar expressions are intended to identify forward-looking statements. These statements are based on management’s current expectations and are qualified in their entirety by the risks described more fully in the Company’s filings with the U.S. Securities and Exchange Commission. Any forward-looking statement regarding future revenues, market penetration, or operational expansion reflects management’s current belief only and should not be read as a guarantee of any outcome. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.

Contact

info@stemcellsgroup.com

Read more
  • Published in Press Releases
No Comments

ISSCA Launches Peptide Certification 2.0 With Expanded Curriculum and Two New Reference Books

Thursday, August 13, 2026 by Sarah Barroso

FOR IMMEDIATE RELEASE

  • Major expansion of ISSCA’s peptide education program includes updated modules, practical resources, and two new physician reference books
  • Program addresses dosing frameworks, combination strategies, preparation, and protocol development within applicable medical and regulatory frameworks
  • Peptide Certification 2.0 builds on ISSCA’s existing physician education infrastructure

MIAMI, FL — The International Society for Stem Cell Application (ISSCA), the physician-education division of Global Stem Cells Group and Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG), today announced Peptide Certification 2.0, a major expansion of its peptide medicine education and certification program.

The updated program includes expanded curriculum modules, updated educational materials, practical physician resources, and two new specialized peptide reference guides addressing dosing frameworks, combination strategies, preparation, and protocol development within applicable medical and regulatory frameworks.

ISSCA positioned Peptide Certification 2.0 as a comprehensive physician-focused educational resource, building on the organization’s existing peptide certification track offered at its conference programming across Latin America, the Middle East, and other regions.

“Peptide medicine has moved fast, and the education has to keep pace with it,” said David Christensen, Chief Executive Officer and President of Regenerative Medical Technology Group, Inc. “Version 2.0 gives physicians a genuinely updated curriculum and two reference resources they can use in daily practice.”

About Regenerative Medical Technology Group, Inc.

Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG) is an SEC-reporting regenerative medicine company operating through its wholly owned subsidiary Global Stem Cells Group and Global Stem Cells Group’s operating divisions — Cellgenic, the International Society for Stem Cell Application (ISSCA), and Cellular Hope Institute. The Company’s network reaches physicians and patients across more than 30 countries, combining biologics and regenerative-medicine product commercialization, physician education and certification, and physician-directed clinical services. RMTG’s stated mission is to help physicians make the benefits of regenerative medicine available to patients worldwide.

About ISSCA

The International Society for Stem Cell Application (ISSCA), the physician-education division of Global Stem Cells Group and Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG), was founded in 2009 and has trained more than 12,000 physicians across more than 45 countries in regenerative medicine, longevity medicine, and related disciplines through certifications, fellowships, conferences, and online education.

Forward-Looking Statements

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, and other factors — including regulatory developments, market acceptance, operational execution, competitive conditions, currency and economic factors, and the Company’s ability to maintain compliance with applicable laws — that could cause actual results to differ materially from those expressed or implied. Words such as “plan,” “forecast,” “anticipate,” “estimate,” “project,” “intend,” “expect,” “should,” “believe,” and similar expressions are intended to identify forward-looking statements. These statements are based on management’s current expectations and are qualified in their entirety by the risks described more fully in the Company’s filings with the U.S. Securities and Exchange Commission. Any forward-looking statement regarding future revenues, market penetration, or operational expansion reflects management’s current belief only and should not be read as a guarantee of any outcome. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.

Contact

info@stemcellsgroup.com

Read more
  • Published in Press Releases
No Comments

ISSCA Expands Global Online Academy With New Curriculum Modules

Thursday, August 13, 2026 by Sarah Barroso

FOR IMMEDIATE RELEASE

  • Expansion adds modules covering biologics, exosomes, MSCs, NK cells, dendritic cells, immunotherapy, CAR-T science, peptide medicine, and longevity medicine
  • Next generation of ISSCA’s Online Academy broadens physician access to regenerative medicine education
  • Curriculum growth complements ISSCA’s in-person conference and certification programs

MIAMI, FL — The International Society for Stem Cell Application (ISSCA), the physician-education division of Global Stem Cells Group and Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG), today announced the next generation of its Online Academy, adding curriculum modules covering biologics, exosomes, mesenchymal stromal/stem cells (MSCs), Natural Killer cells, dendritic cells, immunotherapy, CAR-T cell science, peptide medicine, longevity medicine, and other emerging regenerative technologies.

The expanded Academy is designed to give physicians outside ISSCA’s in-person conference markets ongoing access to structured, updated regenerative-medicine education. ISSCA said the expansion reflects sustained physician demand for digital-first education formats alongside its conference and certification programming.

The organization was clear that Online Academy modules constitute physician education and do not themselves authorize any physician to administer a particular therapy — authorization remains governed by each physician’s own licensure and applicable local regulation.

“Not every physician can travel to a conference for every new modality,” said David Christensen, Chief Executive Officer and President of Regenerative Medical Technology Group, Inc. “Expanding the Online Academy is how ISSCA keeps a much larger physician population current, between the in-person events we run around the world.”

About Regenerative Medical Technology Group, Inc.

Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG) is an SEC-reporting regenerative medicine company operating through its wholly owned subsidiary Global Stem Cells Group and Global Stem Cells Group’s operating divisions — Cellgenic, the International Society for Stem Cell Application (ISSCA), and Cellular Hope Institute. The Company’s network reaches physicians and patients across more than 30 countries, combining biologics and regenerative-medicine product commercialization, physician education and certification, and physician-directed clinical services. RMTG’s stated mission is to help physicians make the benefits of regenerative medicine available to patients worldwide.

About ISSCA

The International Society for Stem Cell Application (ISSCA), the physician-education division of Global Stem Cells Group and Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG), was founded in 2009 and has trained more than 12,000 physicians across more than 45 countries in regenerative medicine, longevity medicine, and related disciplines through certifications, fellowships, conferences, and online education.

Forward-Looking Statements

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, and other factors — including regulatory developments, market acceptance, operational execution, competitive conditions, currency and economic factors, and the Company’s ability to maintain compliance with applicable laws — that could cause actual results to differ materially from those expressed or implied. Words such as “plan,” “forecast,” “anticipate,” “estimate,” “project,” “intend,” “expect,” “should,” “believe,” and similar expressions are intended to identify forward-looking statements. These statements are based on management’s current expectations and are qualified in their entirety by the risks described more fully in the Company’s filings with the U.S. Securities and Exchange Commission. Any forward-looking statement regarding future revenues, market penetration, or operational expansion reflects management’s current belief only and should not be read as a guarantee of any outcome. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.

Contact

info@stemcellsgroup.com

Read more
  • Published in Press Releases
No Comments

ISSCA Launches Integrative Fellowship in Point-of-Care Regenerative Medicine

Thursday, August 13, 2026 by Sarah Barroso

FOR IMMEDIATE RELEASE

  • New fellowship integrates regenerative medicine, emerging biotechnology, longevity medicine, and artificial intelligence
  • Program targets physicians and point-of-care regenerative medicine providers
  • Curriculum reflects ISSCA’s continued investment in advanced physician credentialing

MIAMI, FL — The International Society for Stem Cell Application (ISSCA), the physician-education division of Global Stem Cells Group and Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG), today announced the launch of a comprehensive new fellowship designed for physicians and point-of-care regenerative medicine providers.

The curriculum integrates regenerative medicine modalities, emerging biotechnology, longevity medicine, clinical implementation, and artificial intelligence — reflecting what ISSCA describes as the increasingly multidisciplinary nature of modern regenerative medicine practice.

ISSCA, founded in 2009, has trained more than 12,000 physicians across more than 45 countries. The new fellowship is positioned as the organization’s most comprehensive credential to date, intended to prepare physicians for the convergence of clinical practice, biotechnology, and computational tools.

“The physicians who will lead this field aren’t going to specialize in just one modality — they’ll need to be fluent across regenerative medicine, biotechnology, and increasingly, AI-driven clinical tools,” said David Christensen, Chief Executive Officer and President of Regenerative Medical Technology Group, Inc. “This fellowship is ISSCA’s answer to that shift.”

About Regenerative Medical Technology Group, Inc.

Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG) is an SEC-reporting regenerative medicine company operating through its wholly owned subsidiary Global Stem Cells Group and Global Stem Cells Group’s operating divisions — Cellgenic, the International Society for Stem Cell Application (ISSCA), and Cellular Hope Institute. The Company’s network reaches physicians and patients across more than 30 countries, combining biologics and regenerative-medicine product commercialization, physician education and certification, and physician-directed clinical services. RMTG’s stated mission is to help physicians make the benefits of regenerative medicine available to patients worldwide.

About ISSCA

The International Society for Stem Cell Application (ISSCA), the physician-education division of Global Stem Cells Group and Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG), was founded in 2009 and has trained more than 12,000 physicians across more than 45 countries in regenerative medicine, longevity medicine, and related disciplines through certifications, fellowships, conferences, and online education.

Forward-Looking Statements

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, and other factors — including regulatory developments, market acceptance, operational execution, competitive conditions, currency and economic factors, and the Company’s ability to maintain compliance with applicable laws — that could cause actual results to differ materially from those expressed or implied. Words such as “plan,” “forecast,” “anticipate,” “estimate,” “project,” “intend,” “expect,” “should,” “believe,” and similar expressions are intended to identify forward-looking statements. These statements are based on management’s current expectations and are qualified in their entirety by the risks described more fully in the Company’s filings with the U.S. Securities and Exchange Commission. Any forward-looking statement regarding future revenues, market penetration, or operational expansion reflects management’s current belief only and should not be read as a guarantee of any outcome. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.

Contact

info@stemcellsgroup.com

Read more
  • Published in Press Releases
No Comments

Cellgenic Sponsors Congreso Internacional Medéstetica 2026 in Buenos Aires

Thursday, August 13, 2026 by Sarah Barroso

FOR IMMEDIATE RELEASE

  • Sponsorship connects Cellgenic to one of Latin America’s largest combined aesthetic, regenerative, and orthomolecular medicine congresses
  • Congreso Medéstetica 2026 runs August 19–21 at Salguero Plaza, Buenos Aires, organized by Portal Medestética
  • Event combines four concurrent programs, a commercial exhibition, and live procedural demonstrations

MIAMI, FL — Cellgenic, the biotechnology and product-commercialization division of Global Stem Cells Group and Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG), today announced its sponsorship of Congreso Internacional Medéstetica 2026 in Buenos Aires, Argentina.

Congreso Medéstetica 2026 runs August 19–21 at Salguero Plaza in Buenos Aires and combines four concurrent programs — the XI International Medical Aesthetics Congress, IV Live Demo Day, the XI Orthomolecular and Integrative Medicine Meeting, and the XIV Cosmiatry and Applied Aesthetics Meeting — alongside a commercial exhibition and live procedural demonstrations, organized by Portal Medestética.

The sponsorship gives Cellgenic direct access to a physician audience spanning aesthetic, regenerative, and orthomolecular medicine, complementing the Company’s existing Argentina commercial operations and reinforcing its regional physician-education and product-visibility strategy.

“Medéstetica brings together exactly the physician disciplines Cellgenic serves — aesthetic, regenerative, and orthomolecular medicine — under one roof,” said David Christensen, Chief Executive Officer and President of Regenerative Medical Technology Group, Inc. “This sponsorship is a natural extension of the commercial footprint we’ve been building in Argentina all year.”

About Regenerative Medical Technology Group, Inc.

Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG) is an SEC-reporting regenerative medicine company operating through its wholly owned subsidiary Global Stem Cells Group and Global Stem Cells Group’s operating divisions — Cellgenic, the International Society for Stem Cell Application (ISSCA), and Cellular Hope Institute. The Company’s network reaches physicians and patients across more than 30 countries, combining biologics and regenerative-medicine product commercialization, physician education and certification, and physician-directed clinical services. RMTG’s stated mission is to help physicians make the benefits of regenerative medicine available to patients worldwide.

About Cellgenic

Cellgenic, the biotechnology and product-commercialization division of Global Stem Cells Group and Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG), develops and distributes advanced cellular technologies, biologics, peptide therapeutics, and related regenerative-medicine products to physicians and clinics in permitted international markets.

Forward-Looking Statements

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, and other factors — including regulatory developments, market acceptance, operational execution, competitive conditions, currency and economic factors, and the Company’s ability to maintain compliance with applicable laws — that could cause actual results to differ materially from those expressed or implied. Words such as “plan,” “forecast,” “anticipate,” “estimate,” “project,” “intend,” “expect,” “should,” “believe,” and similar expressions are intended to identify forward-looking statements. These statements are based on management’s current expectations and are qualified in their entirety by the risks described more fully in the Company’s filings with the U.S. Securities and Exchange Commission. Any forward-looking statement regarding future revenues, market penetration, or operational expansion reflects management’s current belief only and should not be read as a guarantee of any outcome. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.

Contact

info@stemcellsgroup.com

Read more
  • Published in Press Releases
No Comments

Cellgenic Sponsors Master Hub Latam 2026, Latin America’s Leading Aesthetic Medicine Congress

Thursday, August 13, 2026 by Sarah Barroso

FOR IMMEDIATE RELEASE

  • Sponsorship connects Cellgenic’s Argentina commercial operations to Latin America’s leading facial-rejuvenation and aesthetic-medicine congress
  • Master Hub LatAm 2026 runs October 15–16 at the Hilton Buenos Aires, led by scientific director Dr. Fernando Felice
  • Event draws 12+ international speakers across regenerative therapies, injectables, and longevity tracks

MIAMI, FL — Cellgenic, the biotechnology and product-commercialization division of Global Stem Cells Group and Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG), today announced its sponsorship of Master Hub LatAm 2026, described by organizers as the most important aesthetic medicine and facial rejuvenation congress in Latin America.

Master Hub LatAm 2026 takes place October 15–16 at the Hilton Hotel in Buenos Aires, Argentina, under scientific director and founder Dr. Fernando Felice, a plastic surgeon and professor at Universidad de Buenos Aires. The 2026 program features more than 12 international speakers across sessions on regenerative therapies, advanced technologies, neuromodulators, and longevity medicine.

The sponsorship builds on Cellgenic’s July 2026 launch of regulated commercial operations in Argentina, extending the Company’s regional presence into one of the country’s highest-visibility medical-aesthetics events and giving Cellgenic direct access to the congress’s international physician and injector audience.

“Master Hub LatAm is where the region’s leading aesthetic physicians go to see what’s next,” said David Christensen, Chief Executive Officer and President of Regenerative Medical Technology Group, Inc. “Sponsoring this year’s congress puts Cellgenic’s regenerative technologies directly in front of that audience, right as we’re scaling our commercial operations across Argentina.”

About Regenerative Medical Technology Group, Inc.

Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG) is an SEC-reporting regenerative medicine company operating through its wholly owned subsidiary Global Stem Cells Group and Global Stem Cells Group’s operating divisions — Cellgenic, the International Society for Stem Cell Application (ISSCA), and Cellular Hope Institute. The Company’s network reaches physicians and patients across more than 30 countries, combining biologics and regenerative-medicine product commercialization, physician education and certification, and physician-directed clinical services. RMTG’s stated mission is to help physicians make the benefits of regenerative medicine available to patients worldwide.

About Cellgenic

Cellgenic, the biotechnology and product-commercialization division of Global Stem Cells Group and Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG), develops and distributes advanced cellular technologies, biologics, peptide therapeutics, and related regenerative-medicine products to physicians and clinics in permitted international markets.

Forward-Looking Statements

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, and other factors — including regulatory developments, market acceptance, operational execution, competitive conditions, currency and economic factors, and the Company’s ability to maintain compliance with applicable laws — that could cause actual results to differ materially from those expressed or implied. Words such as “plan,” “forecast,” “anticipate,” “estimate,” “project,” “intend,” “expect,” “should,” “believe,” and similar expressions are intended to identify forward-looking statements. These statements are based on management’s current expectations and are qualified in their entirety by the risks described more fully in the Company’s filings with the U.S. Securities and Exchange Commission. Any forward-looking statement regarding future revenues, market penetration, or operational expansion reflects management’s current belief only and should not be read as a guarantee of any outcome. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.

Contact

Investor contact: info@stemcellsgroup.com
Media contact: info@stemcellsgroup.com

Read more
  • Published in Press Releases
No Comments

Cellgenic Expands Operations in Colombia

Thursday, August 13, 2026 by Sarah Barroso

FOR IMMEDIATE RELEASE

  • Expansion adds local infrastructure and physician-provider relationships in Colombia
  • Colombia completes a three-market Latin American expansion alongside Peru and Brazil
  • Growth reflects Cellgenic’s continued investment in regional physician networks

MIAMI, FL — Cellgenic, the biotechnology and product-commercialization division of Global Stem Cells Group and Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG), today announced an operational expansion into Colombia, adding local commercial infrastructure and building physician and medical-provider relationships across the market.

The Colombia expansion follows Cellgenic’s recent moves into Peru and Brazil, and management said it completes a near-term Latin American growth phase focused on Andean and South American markets with established regenerative-medicine physician communities — several of which ISSCA has also served through its Bogotá conference programming.

Cellgenic is pursuing exclusive representation and partnership arrangements in Colombia, consistent with its approach in other markets.

“Colombia rounds out a Latin American expansion phase that’s been deliberate and market-by-market,” said David Christensen, Chief Executive Officer and President of Regenerative Medical Technology Group, Inc. “Between Peru, Brazil, and Colombia, Cellgenic now has meaningfully more regional reach than it did a year ago.”

About Regenerative Medical Technology Group, Inc.

Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG) is an SEC-reporting regenerative medicine company operating through its wholly owned subsidiary Global Stem Cells Group and Global Stem Cells Group’s operating divisions — Cellgenic, the International Society for Stem Cell Application (ISSCA), and Cellular Hope Institute. The Company’s network reaches physicians and patients across more than 30 countries, combining biologics and regenerative-medicine product commercialization, physician education and certification, and physician-directed clinical services. RMTG’s stated mission is to help physicians make the benefits of regenerative medicine available to patients worldwide.

About Cellgenic

Cellgenic, the biotechnology and product-commercialization division of Global Stem Cells Group and Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG), develops and distributes advanced cellular technologies, biologics, peptide therapeutics, and related regenerative-medicine products to physicians and clinics in permitted international markets.

Forward-Looking Statements

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, and other factors — including regulatory developments, market acceptance, operational execution, competitive conditions, currency and economic factors, and the Company’s ability to maintain compliance with applicable laws — that could cause actual results to differ materially from those expressed or implied. Words such as “plan,” “forecast,” “anticipate,” “estimate,” “project,” “intend,” “expect,” “should,” “believe,” and similar expressions are intended to identify forward-looking statements. These statements are based on management’s current expectations and are qualified in their entirety by the risks described more fully in the Company’s filings with the U.S. Securities and Exchange Commission. Any forward-looking statement regarding future revenues, market penetration, or operational expansion reflects management’s current belief only and should not be read as a guarantee of any outcome. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.

Contact

Investor contact: info@stemcellsgroup.com
Media contact: info@stemcellsgroup.com

Read more
  • Published in Press Releases
No Comments

Cellgenic Establishes Permanent Operations in Brazil

Thursday, August 13, 2026 by Sarah Barroso

FOR IMMEDIATE RELEASE

  • New permanent operations and offices support Cellgenic’s commercial buildout in Brazil
  • Brazil expansion reflects the strategic importance of one of Latin America’s largest regenerative medicine and longevity markets
  • Launch builds local physician relationships and commercial infrastructure

MIAMI, FL — Cellgenic, the biotechnology and product-commercialization division of Global Stem Cells Group and Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG), today announced the establishment of permanent operations and offices in Brazil.

Brazil represents one of Latin America’s largest healthcare and aesthetic-medicine markets, and Cellgenic said the buildout includes local representation, physician relationships, and commercial infrastructure intended to support both product distribution and longer-term market development.

The Company noted that Brazil’s scale and existing regenerative-medicine physician community — reinforced by ISSCA’s own conference activity in São Paulo — make it a strategically important market within Cellgenic’s Latin American expansion plan.

“Brazil is one of the largest and most sophisticated regenerative medicine markets in Latin America,” said David Christensen, Chief Executive Officer and President of Regenerative Medical Technology Group, Inc. “A permanent operational presence lets Cellgenic build the kind of long-term physician relationships that market deserves.”

About Regenerative Medical Technology Group, Inc.

Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG) is an SEC-reporting regenerative medicine company operating through its wholly owned subsidiary Global Stem Cells Group and Global Stem Cells Group’s operating divisions — Cellgenic, the International Society for Stem Cell Application (ISSCA), and Cellular Hope Institute. The Company’s network reaches physicians and patients across more than 30 countries, combining biologics and regenerative-medicine product commercialization, physician education and certification, and physician-directed clinical services. RMTG’s stated mission is to help physicians make the benefits of regenerative medicine available to patients worldwide.

About Cellgenic

Cellgenic, the biotechnology and product-commercialization division of Global Stem Cells Group and Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG), develops and distributes advanced cellular technologies, biologics, peptide therapeutics, and related regenerative-medicine products to physicians and clinics in permitted international markets.

Forward-Looking Statements

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, and other factors — including regulatory developments, market acceptance, operational execution, competitive conditions, currency and economic factors, and the Company’s ability to maintain compliance with applicable laws — that could cause actual results to differ materially from those expressed or implied. Words such as “plan,” “forecast,” “anticipate,” “estimate,” “project,” “intend,” “expect,” “should,” “believe,” and similar expressions are intended to identify forward-looking statements. These statements are based on management’s current expectations and are qualified in their entirety by the risks described more fully in the Company’s filings with the U.S. Securities and Exchange Commission. Any forward-looking statement regarding future revenues, market penetration, or operational expansion reflects management’s current belief only and should not be read as a guarantee of any outcome. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.

Contact

Investor contact: info@stemcellsgroup.com
Media contact: info@stemcellsgroup.com

Read more
  • Published in Press Releases
No Comments

Cellgenic Launches Operations in Peru, Expanding Latin American Footprint

Thursday, August 13, 2026 by Sarah Barroso

FOR IMMEDIATE RELEASE

  • Expansion establishes permanent local operations and physician representation in Peru
  • Peru becomes the latest addition to Cellgenic’s Latin American commercial footprint
  • Launch builds on Cellgenic’s existing regional infrastructure and physician relationships

MIAMI, FL — Cellgenic, the biotechnology and product-commercialization division of Global Stem Cells Group and Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG), today announced its expansion into Peru through the establishment of local operations and exclusive representation arrangements.

The Peru launch extends Cellgenic’s Latin American commercial network, which the Company has been building through market entries and local partnerships across the region. Cellgenic intends to develop physician and medical-provider relationships in Peru consistent with its approach in other Latin American markets.

Management said Peru fits within Cellgenic’s broader Latin American expansion strategy and represents an additional near-term commercial growth opportunity for the division.

“Peru has a strong and growing physician community interested in regenerative medicine,” said David Christensen, Chief Executive Officer and President of Regenerative Medical Technology Group, Inc. “Establishing a permanent presence there is a natural next step in building out Cellgenic’s Latin American network.”

About Regenerative Medical Technology Group, Inc.

Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG) is an SEC-reporting regenerative medicine company operating through its wholly owned subsidiary Global Stem Cells Group and Global Stem Cells Group’s operating divisions — Cellgenic, the International Society for Stem Cell Application (ISSCA), and Cellular Hope Institute. The Company’s network reaches physicians and patients across more than 30 countries, combining biologics and regenerative-medicine product commercialization, physician education and certification, and physician-directed clinical services. RMTG’s stated mission is to help physicians make the benefits of regenerative medicine available to patients worldwide.

About Cellgenic

Cellgenic, the biotechnology and product-commercialization division of Global Stem Cells Group and Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG), develops and distributes advanced cellular technologies, biologics, peptide therapeutics, and related regenerative-medicine products to physicians and clinics in permitted international markets.

Forward-Looking Statements

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, and other factors — including regulatory developments, market acceptance, operational execution, competitive conditions, currency and economic factors, and the Company’s ability to maintain compliance with applicable laws — that could cause actual results to differ materially from those expressed or implied. Words such as “plan,” “forecast,” “anticipate,” “estimate,” “project,” “intend,” “expect,” “should,” “believe,” and similar expressions are intended to identify forward-looking statements. These statements are based on management’s current expectations and are qualified in their entirety by the risks described more fully in the Company’s filings with the U.S. Securities and Exchange Commission. Any forward-looking statement regarding future revenues, market penetration, or operational expansion reflects management’s current belief only and should not be read as a guarantee of any outcome. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.

Contact

Investor contact: info@stemcellsgroup.com
Media contact: info@stemcellsgroup.com

Read more
  • Published in Press Releases
No Comments

Cellgenic Expands Cancun Laboratory Infrastructure With Two Additional Clean Rooms

Thursday, August 13, 2026 by Sarah Barroso

FOR IMMEDIATE RELEASE

  • Expansion adds two ISO 7-classified clean rooms to existing laboratory infrastructure
  • Investment is intended to support increased manufacturing, quality systems, and product-development capacity
  • Infrastructure expansion supports Cellgenic’s growing international product portfolio

MIAMI, FL — Cellgenic, the biotechnology and product-commercialization division of Global Stem Cells Group and Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG), today announced an expansion of its flagship laboratory facilities in Cancun, Mexico, adding two ISO 7-classified clean rooms to the Company’s existing laboratory infrastructure.

The additional capacity is intended to support increased manufacturing capabilities, product development throughput, and quality-systems capacity as Cellgenic’s international product portfolio continues to grow — including the Company’s recently announced NK cell and MUSE cell product lines and expanded peptide delivery portfolio.

The Company characterized the investment as an important component of its long-term international growth strategy, supporting both current production volume and future product-line development.

“Manufacturing and quality infrastructure is what lets a product roadmap turn into reliable, scalable supply,” said David Christensen, Chief Executive Officer and President of Regenerative Medical Technology Group, Inc. “This clean room expansion in Cancun gives Cellgenic the capacity it needs to support the product lines we’ve been bringing to market this year.”

About Regenerative Medical Technology Group, Inc.

Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG) is an SEC-reporting regenerative medicine company operating through its wholly owned subsidiary Global Stem Cells Group and Global Stem Cells Group’s operating divisions — Cellgenic, the International Society for Stem Cell Application (ISSCA), and Cellular Hope Institute. The Company’s network reaches physicians and patients across more than 30 countries, combining biologics and regenerative-medicine product commercialization, physician education and certification, and physician-directed clinical services. RMTG’s stated mission is to help physicians make the benefits of regenerative medicine available to patients worldwide.

About Cellgenic

Cellgenic, the biotechnology and product-commercialization division of Global Stem Cells Group and Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG), develops and distributes advanced cellular technologies, biologics, peptide therapeutics, and related regenerative-medicine products to physicians and clinics in permitted international markets.

Forward-Looking Statements

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, and other factors — including regulatory developments, market acceptance, operational execution, competitive conditions, currency and economic factors, and the Company’s ability to maintain compliance with applicable laws — that could cause actual results to differ materially from those expressed or implied. Words such as “plan,” “forecast,” “anticipate,” “estimate,” “project,” “intend,” “expect,” “should,” “believe,” and similar expressions are intended to identify forward-looking statements. These statements are based on management’s current expectations and are qualified in their entirety by the risks described more fully in the Company’s filings with the U.S. Securities and Exchange Commission. Any forward-looking statement regarding future revenues, market penetration, or operational expansion reflects management’s current belief only and should not be read as a guarantee of any outcome. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.

Contact

Investor contact: info@stemcellsgroup.com
Media contact: info@stemcellsgroup.com

Read more
  • Published in Press Releases
No Comments
  • 1
  • 2
  • 3
  • 4
  • 5

Send Us a Message

Contact Home GSCG website

Name(Required)
Email(Required)
*
Please let us know what's on your mind. Have a question for us? Ask away.
  • Home
  • Our Story
  • Speakers
  • Investors
  • Companies
  • Testimonials
  • Press Releases
  • Blog

Copyright © 2024 Stem Cells Group | All Rights Reserved | Privacy Policy and Terms and Conditions

CONTACT US

Datran Center 9100 S Dadeland Boulevard, Suite 1500. Miami Fl. 33156 United States

305-560-5337

info@stemcellsgroup.com

STAY CONNECTED

Get the latest news, updates, and promotions. Follow us on our social networks.

Certification issued by ISSCA

  • Home
  • Our Story
  • Speakers
  • Investors
  • Companies
  • Testimonials
  • Press Releases
  • Blog

Copyright © 2024 Stem Cells Group | All Rights Reserved | Privacy Policy and Terms and Conditions

CONTACT US

Datran Center 9100 S Dadeland Boulevard, Suite 1500. Miami Fl. 33156 United States

305-560-5337

info@stemcellsgroup.com

STAY CONNECTED

Get the latest news, updates, and promotions. Follow us on our social networks.

Certification issued by ISSCA

TOP